Inactive Instrument

Press Releases Celltrion, Inc. Korea S.E.

Equities

068270

KR7068270008

End-of-day quote Korea S.E. Other stock markets
- ^KRW	-

Apr. 24	Market Share of Celltrion’s Remsima Rises to 74% in Europe	MT
Apr. 17	Celltrion, Inc. announces an Equity Buyback for 436,047 shares.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MDL Panel Grants Transfer Of Aflibercept BPCIA Case	Apr. 22	AQ
Updates On Aflibercept BPCIA Litigation	Mar. 26	AQ
Fresenius Kabi's Actemra® Biosimilar Tyenne® (Tocilizumab-aazg) Approved In The U.S.	Mar. 20	AQ
Genentech And Partners Voluntarily Dismiss IPR Appeals Related To Genentech's ACTEMRA® (Tocilizumab)	Mar. 05	AQ
PTAB Institutes Celltrion And Biocon IPRs On Regeneron Aflibercept Dosing Patent	Feb. 29	AQ
Celltrion Submits An ABLA For Actemra® (Tocilizumab) Proposed Biosimilar CT-P47	Feb. 29	AQ
Chugai, Genentech, And Hoffmann-La Roche Dismiss Appeals Of Actemra® Patent IPR Final Written Decisions	Feb. 29	AQ
Updates On Aflibercept BPCIA Litigation	Feb. 19	AQ
Celltrion Launches 80 Mg YUFLYMA (Adalimumab-aaty) In The U.S.	Feb. 05	AQ
PTAB Issues Final Written Decisions Finding Claims Of Aflibercept-Related Patents Invalid	Jan. 26	AQ
Celltrion presents strategic vision and growth plan at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 12	AQ
Regeneron's Disputes With Celltrion, Samsung Bioepis, And Formcycon On Service And Personal Jurisdiction In Aflibercept BPCIA Litigation	Jan. 11	AQ
Celltrion Completes Application For FDA Approval Of CT-P41, Biosimilar Of Prolia® / Xgeva®	Jan. 02	AQ
Regeneron Sues Celltrion For Proposed Biosimilar Of Eylea In West Virginia District Court	Nov. 20	AQ
Celltrion Announces FDA Approval Of ZYMFENTRA (Infliximab-dyyb)	23-10-31	AQ
Celltrion Expands Access To YUFLYMA (Adalimumab-Aaty)	23-10-19	AQ
Relapsing Remitting Multiple Sclerosis Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)	23-09-26	AQ
Celltrion : ConsolidatedFS_1H FY2023	23-09-05	PU
Samsung Bioepis Files IPR Petition Challenging Regeneron Aflibercept Patent	23-08-23	AQ
Regeneron Moves To Terminate Celltrion IPR On Aflibercept Patent After Regeneron Files Statutory Disclaimer	23-08-15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Celltrion, Inc. Korea S.E.

Equities

068270

KR7068270008

Press Releases

Filters